You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.
The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.